Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.

2 Jun 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.

2 Jun 2015

New treatment option for postmenopausal women with non-invasive breast cancer

Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen.

2 Jun 2015

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).

2 Jun 2015

Surgical resection, chemo and radiation therapy combination could benefit metastatic NSCLC patients

Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.

2 Jun 2015

SIRFLOX study promises better and earlier treatment option for liver cancer patients

The benefits of adding liver-directed SIR-Spheres Y-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (mCRC) reported in the SIRFLOX study, were presented at the American Society of Clinical Oncology Annual Meeting in Chicago.

2 Jun 2015

WBRT associated with worse cognitive function than radiosurgery, shows study

Whole Brain Radiation Therapy (WBRT) is associated with significantly worse cognitive function than radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery to treat cancer patients with brain metastases, according to a large study led by a researcher at The University of Texas MD Anderson Cancer Center.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).

1 Jun 2015

Decipher Prostate Cancer Classifier predicts metastasis in patients treated with salvage radiation therapy

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant predictor of metastasis in patients treated with postoperative salvage radiation therapy.

30 May 2015

Acupuncture-like TENS may be effective for treating radiation-induced xerostomia

Phase III results of Radiation Therapy Oncology Group 0537 indicate that acupuncture-like, transcutaneous electrical nerve stimulation (ALTENS) may be equally effective as pilocarpine, the current prescription medication in a pill, to treat radiation-induced xerostomia (dry mouth), according to a study published in the June 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology.

30 May 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

Neurosurgeon performs first endoscopic removal of spinal tumor at Rhode Island Hospital

The spinal tumor grew back. Even though the 16-year old patient endured surgery a year earlier to remove and diagnose the lesion, it was back and its cause unknown. Determined to identify the tumor tissue and set the patient on an appropriate treatment regimen, Albert Telfeian, M.D., a neurosurgeon at Rhode Island Hospital and Hasbro Children's Hospital, performed the first reported case of extracting the tumor endoscopically while the patient was awake and under a local anesthetic.

29 May 2015

DITTA attends Sixty-Eighth World Health Assembly session held in Geneva

DITTA, the Global Diagnostic Imaging, Healthcare IT and Radiation Therapy Trade Association is, for the first time, attending the World Health Organization’s Sixty-Eighth World Health Assembly from 18-26 May 2015 since DITTA granted the status of NGO in official relationship with WHO.

28 May 2015

New nationwide survey shows steady increase in pediatric patients treated with proton radiation therapy

Results from a new nationwide survey announced today indicate a steady increase in the number of pediatric patients who are being treated with proton radiation therapy for cancerous and non-cancerous tumors.

24 May 2015

Esophageal cancer patients treated with proton therapy experience less toxic side effects

New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.

24 May 2015

Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Merus Labs International Inc. is pleased to announce that one of its wholly owned subsidiaries has signed a definitive agreement to acquire the rights to manufacture, market, and sell two established specialty pharmaceutical products in certain European and other markets.

22 May 2015

Scripps Proton Therapy Center reports exceptional results in treating patients with pencil-beam scanning

The nation's first and only proton therapy center to treat patients exclusively with pencil-beam scanning is reporting exceptional results in delivering cancer treatment since opening for patient care just more than a year ago.

21 May 2015

Radiation Therapy News and Research

Further Reading

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

New treatment option for postmenopausal women with non-invasive breast cancer

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

Surgical resection, chemo and radiation therapy combination could benefit metastatic NSCLC patients

SIRFLOX study promises better and earlier treatment option for liver cancer patients

WBRT associated with worse cognitive function than radiosurgery, shows study

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Decipher Prostate Cancer Classifier predicts metastasis in patients treated with salvage radiation therapy

Acupuncture-like TENS may be effective for treating radiation-induced xerostomia

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Neurosurgeon performs first endoscopic removal of spinal tumor at Rhode Island Hospital

DITTA attends Sixty-Eighth World Health Assembly session held in Geneva

New nationwide survey shows steady increase in pediatric patients treated with proton radiation therapy

Esophageal cancer patients treated with proton therapy experience less toxic side effects

Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Scripps Proton Therapy Center reports exceptional results in treating patients with pencil-beam scanning

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News